| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 9 | -732K | 100% | $2.49 | -$1.82M |
| Net | -9 | -732K | -100% | -$1.82M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Qian Zhang | Associate VP, Research | $1.98M | Feb 17, 2023 | ||
| Aladar Szalay | 10%+ Owner | $1.55M | -$1.72M | -52.5% | Sep 12, 2024 |
| John Thomas | Director | $1.07M | Aug 1, 2024 | ||
| Thomas Zindrick | President and CEO, Director | $497K | -$33.5K | -6.31% | Mar 14, 2025 |
| Lourie S. Zak | Chief Financial Officer | $193K | -$4.92K | -2.49% | Dec 18, 2024 |
| Gabe Woodward | Director | $175K | Feb 17, 2023 | ||
| Joseph Cappello | VP, Pharmaceutical Development | $140K | -$14.7K | -9.51% | Mar 14, 2025 |
| Yong Yu | VP, Clinical Trial Operations | $131K | -$14.5K | -9.98% | Mar 14, 2025 |
| Sean Ryder | General Counsel | $128K | -$11.7K | -8.33% | Mar 14, 2025 |
| James L. Tyree | Director | $113K | -$8.51K | -7.03% | Dec 30, 2024 |
| John W. Smither | Director | $112K | Aug 1, 2024 | ||
| Mary Mirabelli | Director | $110K | Aug 1, 2024 | ||
| Ralph Smalling | Head of Regulatory | $88.6K | -$5.87K | -6.22% | Mar 14, 2025 |
| Caroline Jewett | Head of Quality | $34.3K | -$10.5K | -23.5% | Feb 19, 2024 |
| Doug Samuelson | Vice President, Finance | $32.6K | Sep 11, 2023 | ||
| Paul Scigalla | Chief Medical Officer | Oct 18, 2024 | |||
| Matthew Pulisic | Chief Financial Officer | Jan 31, 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|